All In Biotech

Drug Trial Radar · NCT04276883

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

380

Actual

Start

Feb 24, 2020

Primary completion

May 21, 2020

Study completion May 21, 2020

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Cognitive Research Corporation
First posted
Feb 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.

Conditions

  • Agitation Associated With Bipolar Disorder
  • Agitation,Psychomotor
  • Bipolar Disorder

Interventions

  • Sublingual film containing Dexmedetomidine (BXCL501)Drug

    Sublingual film containing Dexmedetomidine (BXCL501)

  • Placebo FilmDrug

    Placebo Film for BXCL501

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total ScoreTime frame: Baseline and 120 minutes

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site

    Little Rock, Arkansas

  • BioXcel Clinical Research Site

    Cerritos, California

  • BioXcel Clinical Research Site

    Culver City, California

  • BioXcel Clinical Research Site

    Long Beach, California

  • BioXcel Clinical Research Site

    Orange, California

  • BioXcel Clinical Research Site

    Miami Lakes, Florida

  • BioXcel Clinical Research Site

    Chicago, Illinois

  • BioXcel Clinical Research Site

    Gaithersburg, Maryland

  • BioXcel Clinical Research Site

    Las Vegas, Nevada

  • BioXcel Clinical Research Site

    Berlin, New Jersey

  • BioXcel Clinical Research Site

    Marlton, New Jersey

  • BioXcel Clinical Research Site

    Charleston, South Carolina

  • BioXcel Clinical Research Site

    Austin, Texas

  • BioXcel Clinical Research Site

    DeSoto, Texas

  • BioXcel Clinical Research Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.